NGEN Stock Forecast & Price Target

NervGen Pharma is a promising company with a potential firm value of $1.67B and a projected price per share of $18 due to the potential for high sales from their drug NVG-291, which has shown promising results in clinical trials for spinal cord injuries and other neurological conditions, and the potential for future treatments for conditions such as hearing loss and traumatic brain injury through their drug pipeline and the drug's mechanism of inhibiting CSPGs. The RESTORE trial, expected to start enrolling patients in mid-2026, could also lead to FDA approval by mid-2028, increasing the company's market potential.

NervGen Pharma is a clinical-stage biopharmaceutical company that has a negative outlook on its stock due to the fact that its initial target indication, spinal cord injury, includes patients who have not seen functional recovery. Additionally, the company is targeting a single myelin inhibitor, leaving the broader CSPG inhibitory matrix intact which has been a historically difficult area to target with previous drugs. Despite having a pipeline with IP protection beyond 2040 and a potential 12-year BLA exclusivity runway, the company may not see profitability until 2030 at the earliest and may struggle to establish and maintain sales and marketing infrastructure due to competition from larger, more entrenched firms.